FB
FOLD

Fulton Bank’s Amicus Therapeutics FOLD Stock Holding History

Fulton Bank’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,257
Closed -$102K – 664
2024
Q2 		$102K Hold
10,257
– – ﹤0.01% 621
2024
Q1 		$121K Sell
10,257
-1,172
-10% -$15K 0.01% 600
2023
Q4 		$162K Sell
11,429
-305
-3% -$3.46K 0.01% 580
2023
Q3 		$143K Buy
11,734
+245
+2% +$3.16K 0.01% 554
2023
Q2 		$144K Sell
11,489
-383
-3% -$4.54K 0.01% 547
2023
Q1 		$132K Buy
11,872
+123
+1% +$1.52K 0.01% 548
2022
Q4 		$144K Buy
+11,749
New +$132K 0.01% 512
2022
Q2 		– Sell
-10,523
Closed -$99K – 499
2022
Q1 		$99K Sell
10,523
-365
-3% -$3.42K ﹤0.01% 505
2021
Q4 		$125K Buy
+10,888
New +$121K 0.01% 531

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fulton Bank's FOLD Position: Q3 2024 in Review

Fulton Bank sold out of Amicus Therapeutics (FOLD) in Q3 2024, closing a stake of 10,257 shares — an estimated $102K sold.

Fulton Bank first reported a position in FOLD in Q4 2021 and held it in 9 quarters. The position peaked at $162K in Q4 2023. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

  • Fulton Bank reported no remaining Amicus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Fulton Bank sold 10,257 Amicus Therapeutics shares in Q3 2024, an estimated $102K.
  • Fulton Bank first reported a position in Amicus Therapeutics in Q4 2021 and held it in 9 quarters.
  • Fulton Bank's Amicus Therapeutics position peaked at $162K in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on Fulton Bank's 13F filing for Q3 2024, filed 7 Oct 2024.